PMID- 18327398
OWN - NLM
STAT- MEDLINE
DCOM- 20080515
LR  - 20080310
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 99
IP  - 3
DP  - 2008 Mar
TI  - Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the 
      inpatient and outpatient settings.
PG  - 502-10
LID - 10.1160/TH07-08-0500 [doi]
AB  - Pulmonary embolism (PE) remains a major clinical problem associated with 
      considerable mortality and morbidity. In patients with PE, appropriate 
      anticoagulant therapy has been shown to significantly reduce both recurrence and 
      mortality. Low-molecular-weight heparin (LMWH) is at least as effective as 
      unfractionated heparin (UFH) in the treatment of PE, with a similar risk of 
      bleeding. Furthermore, LMWH offers more predictable pharmacokinetics and 
      anticoagulant effects. As a result, current guidelines from both the American 
      College of Chest Physicians and the joint American College of Physicians/American 
      Academy of Family Physicians recommend the use of LMWH over UFH (in patients with 
      submassive PE). Outpatient treatment with LMWH has been shown to be feasible in 
      many patients, and offers the potential for cost-savings and improvements in 
      health-related quality of life. Further data are needed to support an 
      evidence-based recommendation for the use of LMWH in the outpatient treatment of 
      PE.
FAU - Hull, Russell D
AU  - Hull RD
AD  - Thrombosis Research Unit, 601 South Tower Foothills Hospital, 1403-29 Street NW, 
      Calgary, Alberta, Canada T2N 2T9. rdhull@ucalgary.ca
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - *Ambulatory Care
MH  - Anticoagulants/adverse effects/economics/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Cost-Benefit Analysis
MH  - Evidence-Based Medicine
MH  - Health Care Costs
MH  - Hemorrhage/chemically induced
MH  - Heparin, Low-Molecular-Weight/adverse effects/economics/*therapeutic use
MH  - Humans
MH  - *Inpatients
MH  - Long-Term Care
MH  - Patient Selection
MH  - Practice Guidelines as Topic
MH  - Pulmonary Embolism/*drug therapy/economics/etiology/prevention & control
MH  - Quality of Life
MH  - Research Design
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Venous Thrombosis/complications/*drug therapy/economics
RF  - 71
EDAT- 2008/03/11 09:00
MHDA- 2008/05/16 09:00
CRDT- 2008/03/11 09:00
PHST- 2008/03/11 09:00 [pubmed]
PHST- 2008/05/16 09:00 [medline]
PHST- 2008/03/11 09:00 [entrez]
AID - 08030502 [pii]
AID - 10.1160/TH07-08-0500 [doi]
PST - ppublish
SO  - Thromb Haemost. 2008 Mar;99(3):502-10. doi: 10.1160/TH07-08-0500.